News

Search For News


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

1. Chronos Therapeutics Strengthens Management Team with Appointment of D

Chronos Therapeutics Strengthens Management Team with Appointment of Dr Fraser Murray and Dr Timothy Schulz-Utermoehl as Vice Presidents of Pre-Clinical Development 04/08/2016ChronosChronos Therapeutics Ltd (Chronos), the private biotech company focused on ageing diseases, brain and nervous system disorders, today announced the appointment of Dr Fraser Murray and Dr Timothy Schulz-Utermoehl, as Vice Presidents of Pre-Clinical Development.Fraser and Timothy join Chronos from Polleo Pharma, a


2. ViiV Healthcare Launches Phase III Programme Evaluating a Two-drug Reg

ViiV Healthcare Launches Phase III Programme Evaluating a Two-drug Regimen Combining Dolutegravir and Lamivudine for HIV-1 Treatment 16/08/2016ViiV Healthcare today announced the start of a phase III programme to support regulatory filings for a two-drug regimen of dolutegravir (Tivicay®) and lamivudine (Epivir®) as a treatment for HIV-1 infection in adults who have not received prior antiretroviral therapy.The phase III programme comprises two identical studies (GEMINI 1 and 2) c


3. Cambridge Innovation Capital Raises £75 Million via Private Financing

Cambridge Innovation Capital Raises £75 Million via Private Financing19/08/2016Cambridge Innovation Capital plc (“CIC” or “the Company”), a preferred investor for the University of Cambridge and a Cambridge-based investor in technology and healthcare companies, announces that it has raised £75m of new capital (the “Fundraising”).CIC was founded in 2013 as an initiative by the University of Cambridge to create a local entity that would be able to prov


4. Consilium Strategic Communications Advises Cambridge Innovation Capita

Consilium Strategic Communications Advises Cambridge Innovation Capital on Its £75m Fundraise 22/08/2016Consilium Strategic Communications, a global leader in strategic healthcare communications, is pleased to have advised Cambridge Innovation Capital (“CIC”) on its over-subscribed £75 million private financing round.CIC is a preferred investor for the University of Cambridge and has a unique relationship with Cambridge Enterprise, the commercialisation arm of the Univ


5. AstraZeneca to Sell Small Molecule Antibiotics Business to Pfizer. Val

AstraZeneca to Sell Small Molecule Antibiotics Business to Pfizer. Value-creating Divestment Supports AstraZeneca’s Focus on Three Main Therapy Areas 24/08/2016> Pfizer’s dedicated focus on infectious diseases will extend the reach of the antibiotics to more patients globally and maximise the potential of the late-stage, small molecule antibiotics businessAstraZeneca today announced that it has entered into an agreement with Pfizer Inc. (Pfizer) to sell the commercialisation



Page 15 of 30 ( 148 results in total )
© Catalyst Innovation Portal 2019